

Press Release

December 4, 2025

TOWA PHARMACEUTICAL CO., LTD.

## Listing of Five Ingredients and Ten New Products (New Generics) in the NHI Drug Price Standard

Osaka, Japan, December 4, 2025 – Towa Pharmaceutical Co., Ltd. (Towa) is pleased to announce that it will start selling new products (new generics) sequentially on or after December 5, the effective date of their listing in the NHI Drug Price Standard, following public notice in the official gazette on December 4.

Manufacturing and marketing approval for PRASUGREL TABLETS / OD TABLETS “TOWA” has been obtained as authorized generics (AG) of EFIENT® TABLETS / OD TABLETS under a license from Daiichi Sankyo, Co., Ltd., and these products will be on sale from March 3, 2026.

As a result, the number of Towa's products will be 316 ingredients and 742 items.

### <<The list of new products>>

#### 1. PRASUGREL TABLETS

Product name	PRASUGREL TABLETS 2.5mg/3.75mg/5mg “TOWA”
Brand-name drugs	EFIENT® TABLETS 2.5mg/3.75mg/5mg

#### 2. PRASUGREL OD TABLETS

Product name	PRASUGREL OD TABLETS 20mg “TOWA”
Brand-name drugs	EFIENT® OD TABLETS 20mg

#### 3. EFINACONAZOLE TOPICAL SOLUTION

Product name	EFINACONAZOLE TOPICAL SOLUTION 10% “TOWA”
Brand-name drugs	CLENAFIN Topical Solution 10%

#### 4. OSELTAMIVIR DS

Product name	OSELTAMIVIR DS 3% “TOWA”
Brand-name drugs	TAMIFLU Dry Syrup 3%

#### 5. LANTHANUM CARBONATE OD TABLETS

Product name	LANTHANUM CARBONATE OD TABLETS 250mg/ 500mg “TOWA”
Brand-name drugs	Fosrenol OD tablets 250mg/500mg

#### 6. EPINASTINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Product name	EPINASTINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.05% “TW”
Brand-name drugs	ALESION Ophthalmic Solution 0.05%



## 7. EPINASTINE HYDROCHLORIDE LX OPHTHALMIC SOLUTION

Product name	EPINASTINE HYDROCHLORIDE LX OPHTHALMIC SOLUTION 0.1% “TOWA”
Brand-name drugs	ALESION LX Ophthalmic Solution 0.1%

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

### [Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan  
Tel: +81-6-6900-9102 / Email: [kouhou@towayakuhin.co.jp](mailto:kouhou@towayakuhin.co.jp)